http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
개별검색 DB통합검색이 안되는 DB는 DB아이콘을 클릭하여 이용하실 수 있습니다.
통계정보 및 조사
예술 / 패션
<해외전자자료 이용권한 안내>
- 이용 대상 : RISS의 모든 해외전자자료는 교수, 강사, 대학(원)생, 연구원, 대학직원에 한하여(로그인 필수) 이용 가능
- 구독대학 소속 이용자: RISS 해외전자자료 통합검색 및 등록된 대학IP 대역 내에서 24시간 무료 이용
- 미구독대학 소속 이용자: RISS 해외전자자료 통합검색을 통한 오후 4시~익일 오전 9시 무료 이용
※ 단, EBSCO ASC/BSC(오후 5시~익일 오전 9시 무료 이용)
Background: Patients with drug-eluting stents (DESs) overlap are at greater risk of experiencing major adverse cardiac events (MACE), particularly in terms of need of repeat revascularization and mortality. The aim of this study was to compare safety and efficacy of 4 homogenous overlapping DESs in acute myocardial infarction (AMI) patients. Methods: We selected 1,349 consecutive patients (mean age 62.1±14.9 years, 69.4% male) who received homogenous overlapping stents in diffuse de novo coronary lesions from Korea Acute Myocardial Infarction Registry from Apr. 2006 through Sep. 2010. They were divided into 4 groups based on type of DESs implanted - Paclitaxel (PES), Sirolimus (SES), Zotarolimus (ZES) and Everolimus (EES)-eluting stents. Primary endpoint was 12-month MACE. We also studied EES versus other DESs (PES+SES+ZES). Results: Mean stent length was 26.2±7.5mm and mean stent diameter was 3.1±0.4mm. Average number of stents used per vessel was 2.2±0.5. Incidence of MACE in PES, SES, ZES and EES groups were 9.5%, 9.2%, 7.5% and 3.8% respectively (p=0.013). In EES group, overall MACE and repeat revascularization were lowest, and no incidence of stent thrombosis was observed. Non-fatal MI was highest in PES, almost similar in SES and EES with no incidence in ZES group, p=0.044. Cox proportional hazard analysis revealed no differences in the incidence of primary endpoint (p=0.409). When EES was directly compared to other DESs (PES+SES+ZES) 12-month MACE differed significantly between 2 groups (HR5.052, 1.176-21.702, p=0.029). Conclusion: EES showed lowest incidence of MACE and TLR-driven repeat revascularization among the DESs studied.
Jeong,,Hae,Chang,Ahn,,Youngkeun,Jeong,,Myung,Ho,Chae,,Shung,Chull,Hur,,Seung,Ho,Hong,,Taek,Jong,Kim,,Young,Jo,Seong,,In,Whan,Chae,,Jei,Keon,Rhew,,Jay,Young,Chae,,In,Ho,Cho,,Myeong,Chan,Bae,,Jang,Ho,Rh Yonsei University College of Medicine 2010 Yonsei medical journal Vol.51 No.1
<P><B>Purpose</B></P><P>There is still debate about the timing of revascularization in patients with acute non-ST-segment elevation myocardial infarction (NSTEMI). We analyzed the long-term clinical outcomes of the timing of revascularization in patients with acute NSTEMI obtained from the Korea Acute Myocardial Infarction Registry (KAMIR).</P><P><B>Materials and Methods</B></P><P>2,845 patients with acute NSTEMI (65.6 ± 12.5 years, 1,836 males) who were enrolled in KAMIR were included in the present study. The therapeutic strategy of NSTEMI was categorized into early invasive (within 48 hours, 65.8 ± 12.6 years, 856 males) and late invasive treatment (65.3 ± 12.1 years, 979 males). The initial- and long-term clinical outcomes were compared between two groups according to the level of Thrombolysis In Myocardial Infarction (TIMI) risk score.</P><P><B>Results</B></P><P>There were significant differences in-hospital mortality and the incidence of major adverse cardiac events during one-year clinical follow-up between two groups (2.1% vs. 4.8%, <I>p</I> < 0.001, 10.0% vs. 13.5%, <I>p</I> = 0.004, respectively). According to the TIMI risk score, there was no significant difference of long-term clinical outcomes in patients with low to moderate TIMI risk score, but significant difference in patients with high TIMI risk score (≥ 5 points).</P><P><B>Conclusions</B></P><P>The old age, high Killip class, low ejection fraction, high TIMI risk score, and late invasive treatment strategy are the independent predictors for the long-term clinical outcomes in patients with NSTEMI.</P>
Jeong,,Hae,Chang,Jeong,,Ji,Min,Jeong,,Myung,Ho,Ahn,,Youngkeun,Chae,,Shung,Chull,Hur,,Seung,Ho,Hong,,Taek,Jong,Kim,,Young,Jo,Seong,,In,Whan,Chae,,Jei,Keon,Rhew,,Jay,Young,Chae,,In,Ho,Cho,,Myeong,Chan,B Elsevier 2012 INTERNATIONAL JOURNAL OF CARDIOLOGY Vol.157 No.3
Jeong,,Hae,Chang,Kim,,Kye,Hun,Cho,,Jae,Yeong,Song,,Ji,Eun,Yoon,,Hyun,Ju,Seon,,Hyun,Ju,Ahn,,Youngkeun,Jeong,,Myung,Ho,Cho,,Jeong,Gwan,Park,,Jong,Chun Korean Society of Echocardiography 2015 Journal of Cardiovascular Ultrasound Vol.23 No.1
<P>A 31-year-old male who had been treated for Churg-Strauss syndrome (CSS) presented with sudden onset of dysarthria. Brain magnetic resonance imaging (MRI) showed acute multifocal bilateral cerebral infarctions suggesting embolic causes. Cardiac MRI showed dilated cardiomyopathy with severe biventricular dysfunction with intracardiac thrombi, and multiple high signal intensity spots in myocardium of the left ventricle with multifocal delayed enhancement suggesting multifocal myocarditis due to small vessel vasculitis associated with CSS. After anticoagulation therapy, treatments for heart failure, and immunosuppressive therapy including parenteral steroids and cyclophosphamide to control CSS, the symptoms and signs of heart failure and cardiac function of the patient were improved. Considering the pathophysiologic mechanism of cardiac involvement in CSS, immunosuppressive therapy to control the disease activity of CSS should be taken into account, besides usual management for heart failure.</P>
Jeong,,Hae,Chang,Ahn,,Joon,Ho,Kim,,Min,Chul,Sim,,Doo,Sun,Park,,Keun,Ho,Hong,,Young,Joon,Kim,,Ju,Han,Jeong,,Myung,Ho,Seung,,Ki-Bae,Chang,,Kiyuk,Ahn,,Youngkeun The Korean Association of Internal Medicine 2019 The Korean Journal of Internal Medicine Vol.34 No.2
<P><B>Background/Aims</B></P><P>The optimal percutaneous coronary intervention (PCI) strategy in patients with acute myocardial infarction (AMI) with multivessel disease (MVD) is uncertain. This study was designed to develop a novel and simple tool for assessing an individualized and optimized PCI strategy in AMI patients with MVD.</P><P><B>Methods</B></P><P>In total, 5,025 patients with AMI from nine centers at two universities were enrolled in the prospective Convergent Registry of Catholic and Chonnam University for Acute Myocardial Infarction (COREA-AMI) registry from January 2004 through December 2009. From among them, we selected 2,630 patients with MVD who were treated by culprit-only or multivessel (MV) PCI. We investigated major adverse cardiac events (MACEs) during a 1-year clinical follow-up. Using a subgroup analysis, we extracted variables for use in the culprit only versus multivessel revascularization (CONVERSE) score, which showed a preference for MV PCI rather than culprit-only PCI for treating MVD.</P><P><B>Results</B></P><P>The CONVERSE score was constructed using eight independent variables (1 point for each variable): age > 65 years, hypertension, diabetes mellitus, high Killip class (III or IV), low left ventricular ejection fraction (≤ 50%), low creatinine clearance (≤ 60 mL/min), high level of high-sensitivity C-reactive protein (≥ 2.0 mg/L), and left anterior descending artery or left main as the nonculprit vessel. The incidence of MACEs increased linearly with the CONVERSE score. The receiver operating characteristic curve showed that the cutoff value was 3 points.</P><P><B>Conclusions</B></P><P>The results suggest that patients with a CONVERSE score of 3 or more should undergo MV PCI.</P>